A Change of Heart: the New Era of Heart Failure Management

AbstractPurpose of ReviewThis review provides in-depth insight into the recently published literature surrounding two new heart failure therapies, sacubitril/valsartan and ivabradine.Recent FindingsSignificant literature has emerged in the last few years supporting the use of both sacubitril/valsartan and ivabradine in patients with chronic heart failure. Both agents were recently approved and included in the 2016 American College of Cardiology, American Heart Association, and Heart Failure Society of America (ACC/AHA/HFSA) Focused Update on New Pharmacological Therapy for Heart Failure.SummarySacubitril/valsartan was found to significantly reduce cardiovascular and all-cause mortality with an acceptable safety profile in those with reduced ejection fraction. Ongoing trials are evaluating sacubitril/valsartan ’s role in the management of patients with preserved ejection fraction, but phase II trials have provided promising results. Ivabradine was found to have a potential role in patients with heart rates ≥70 bpm, despite receiving maximized beta blocker therapy. This recent literature provides sup port for a shift towards a new era in the management of the heart failure patient.
Source: Current Emergency and Hospital Medicine Reports - Category: Emergency Medicine Source Type: research